DSG3 and pemphigus vulgaris: The first described CAAR uses a portion of desmoglein 3 (Dsg3) as its extracellular domain to treat pemphigus vulgaris (PV), an autoimmune blistering disease caused by autoantibodies against the keratinocyte adhesion protein Dsg3.